Bristol-Myers CVR Sinks After FDA Rejects Key Cancer Drug Filing

(Bloomberg) -- Bristol-Myers Squibb Co.’s announcement that U.S. regulators rejected their filing for its Bluebird Bio Inc.-partnered cancer treatment bb2121 raised cause for concern among investor...
BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.